Related references
Note: Only part of the references are listed.Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2
Won Gu Jang et al.
BONE (2011)
Metformin Stimulates Osteoprotegerin and Reduces RANKL Expression in Osteoblasts and Ovariectomized Rats
Qi-Guang Mai et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2011)
Telmisartan alleviates rosiglitazone-induced bone loss in ovariectomized spontaneous hypertensive rats
L. Ma et al.
BONE (2010)
Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2-year follow-up study
Zehra Berberoglu et al.
CLINICAL ENDOCRINOLOGY (2010)
Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes
R. E. Aubert et al.
DIABETES OBESITY & METABOLISM (2010)
Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee
A. Michael Parfitt et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Metformin reverses the deleterious effects of high glucose on osteoblast function
Donghu Zhen et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2010)
Prevalence of Diabetes among Men and Women in China
Wenying Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
Yoon K. Loke et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2009)
Bone health in diabetes: considerations for clinical management
Silvano Adami
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes An Overview of Data from PROactive
John Dormandy et al.
DRUG SAFETY (2009)
The Risk of Fractures Associated with Thiazolidinediones: A Self-controlled Case-Series Study
Ian J. Douglas et al.
PLOS MEDICINE (2009)
Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression
Ippei Kanazawa et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Rosiglitazone-associated fractures in type 2 diabetes - An analysis from a diabetes outcome progression trial (ADOPT)
Steven E. Kahn et al.
DIABETES CARE (2008)
Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: A randomized, placebo-controlled trial
Dorte Glintborg et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Pioglitazone can downregulate bone morphogenetic protein-2 expression induced by high glucose in human umbilical vein endothelial cells
Ming Zhang et al.
PHARMACOLOGY (2008)
Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone
Oxana P. Lazarenko et al.
ENDOCRINOLOGY (2007)
Relationship between bone ingrowth, mineral apposition rate, and osteoblast activity
R. D. Bloebaum et al.
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A (2007)
Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - a meta-analysis
P. Vestergaard
OSTEOPOROSIS INTERNATIONAL (2007)
Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture
Mohsen Janghorbani et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2007)
Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation
AA Ali et al.
ENDOCRINOLOGY (2005)
Bone is a target for the antidiabetic compound rosiglitazone
SO Rzonca et al.
ENDOCRINOLOGY (2004)
Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays
SA Bustin
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2000)
Bone morphogenetic protein-2 stimulates adipogenic differentiation of mesenchymal precursor cells in synergy with BRL 49653 (rosiglitazone)
V Sottile et al.
FEBS LETTERS (2000)
Share Paper
